Plavix
Product Images NDC 53808-0763

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Plavix (NDC 53808-0763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (75 mg 30 Tablets)

Label for Plavix 75 mg tablets, quantity 30, packaged by DOH Central Pharmacy, Tallahassee, FL. The label includes the manufacturer Sanofi, lot number T267A09A, and an expiration date partially visible as 013111. A barcode and UPC 363653117151 are also shown. The product is Rx only.*

FDA Label Image

Chemical Structure (Plavix 01)

Chemical structure of the active ingredient in Plavix, showing the molecular arrangement including aromatic rings, sulfur and chlorine atoms, and a sulfate component indicated by H2SO4.*

FDA Label Image

Figure (Plavix 02)

A line graph comparing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up between aspirin and Plavix. The graph shows two lines, with Plavix having a slightly lower cumulative event rate than aspirin throughout the period. A statistical significance value (P=0.045) is noted on the graph.*

FDA Label Image

Figure (Plavix 03)

A line graph showing the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two lines compare placebo (+ aspirin) and Plavix (+ aspirin), with Plavix showing a lower cumulative event rate across the study period. The graph includes a p-value of 0.00009, indicating statistical analysis.*

FDA Label Image

Figure (Plavix 04)

A hazard ratio forest plot comparing Plavix (with aspirin) versus placebo (with aspirin) across various baseline characteristics and concomitant medication/therapy categories. The chart presents percent event rates and hazard ratios with confidence intervals, indicating which treatment is associated with better outcomes in each subgroup.*

FDA Label Image

Figure (Plavix 05)

A line graph showing the percentage of deaths before first discharge over 28 days since randomization, comparing placebo and clopidogrel groups. The graph notes 1845 deaths (8.1%) for placebo and 1726 deaths (7.5%) for clopidogrel, indicating a 7% proportional risk reduction with clopidogrel (p = 0.03).*

FDA Label Image

Figure (Plavix 06)

A Kaplan-Meier plot showing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization. The graph compares two groups: one receiving placebo and the other clopidogrel, indicating a 9% proportional risk reduction in the clopidogrel group (p = 0.002).*

FDA Label Image

Figure (Plavix 07)

A forest plot chart comparing the percentage of events between Clopidogrel and Placebo groups across various baseline categories such as sex, age, time since onset, systolic blood pressure, heart rate, fibrinolytic agent use, prognostic index, and metoprolol allocation. The plot displays odds ratios with confidence intervals and a global heterogeneity test statistic.*

FDA Label Image

Figure (Plavix 08)

A forest plot comparing the percentage of events between Clopidogrel and placebo groups across categories like Killip class, previous myocardial infarction, and infarct location. The graph includes odds ratios with confidence intervals and heterogeneity tests, showing a proportional reduction of 9% favoring Clopidogrel. Statistical details such as chi-square and p-values are also presented.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.